Quoin Reports Clinically Meaningful Whole Body Response to QRX003 in Pediatric Netherton Syndrome; Second Patient Cleared for Dosing

Reuters

02-04-2025

ASHBURN, VA, April 2, 2025 (EZ Newswire) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ('Quoin' or the 'Company'), a late-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced additional encouraging clinical findings from its ongoing investigator-led study in pediatric Netherton syndrome (NS). After six weeks of continuous whole body treatment with QRX003, the enrolled pediatric patient continues to demonstrate significant clinical benefit, including visibly healed skin, sustained relief from symptoms, and elimination of the need for previously required medications.
Specifically, the patient's skin remains almost entirely healed, underscoring the durability of effect seen with ongoing daily use of QRX003. Importantly, the subject has not required prior medications such as antibiotics, antivirals, antihistamines, or glucocorticoids. The patient's pruritus (itch) remains virtually eliminated, leading to the continuation of restful, uninterrupted sleep—described by the study team as the first sustained period of undisturbed sleep in the patient's life. No adverse events have been reported after six weeks of full body exposure to QRX003.
Based on these results, Quoin has received approval to initiate testing of a second pediatric patient under the same whole body treatment protocol.
Dr. Michael Myers, CEO of Quoin, commented: 'We're very encouraged to see continued improvement in this first pediatric patient following whole body application of QRX003. Her skin is now almost completely healed, and she remains free from previously required medications. Most notably, the pruritus that has severely impacted her quality of life since birth is now nearly eliminated, and she is finally experiencing uninterrupted sleep without the need for sedatives.
These outcomes provide strong evidence that QRX003 may be addressing the underlying pathology of Netherton syndrome—not just managing symptoms. The absence of adverse events after six weeks of full-body exposure is also highly encouraging. With approval now granted to initiate treatment in a second pediatric subject, we look forward to continuing this important study and reporting further updates.'
About Quoin Pharmaceuticals
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton syndrome, peeling skin syndrome, SAM syndrome, palmoplantar keratoderma, scleroderma, epidermolysis bullosa, microcystic lymphatic malformations, venous malformations, angiofibroma, and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as 'expect,' 'intend,' 'hope,' 'plan,' 'potential,' 'anticipate,' 'look forward,' 'believe,' 'may,' and 'will,' among others. All statements that reflect the Company's expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: the potential efficacy of QRX003 as a treatment for Netherton syndrome; testing expected to commence in a few weeks on a second pediatric patient; continue with our plans to further expand this study to include additional pediatric subjects; and Quoin's products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton syndrome, peeling skin syndrome, SAM syndrome, palmoplantar keratoderma, scleroderma, epidermolysis bullosa, microcystic lymphatic malformations, venous malformations, angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company's ability to deliver a safe and effective treatment for Netherton syndrome; whether the Company's studies successfully generate data that is sufficiently robust and comprehensive to support an NDA filing for QRX003 as an approved treatment for Netherton syndrome; and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
Media Contact
###
SOURCE: Quoin Pharmaceuticals